Chelating Agents

01/01/2009 - "In recent years advances in knowledge of iron overload patho-physiopathology, improvement and diffusion of diagnostic capability together with the development of new effective and safe oral chelators promise to further increase success of medical therapy. "
01/01/2015 - "Recent advances in imaging techniques and chelators development remarkably improved cardiac iron overload detection and treatment, respectively. "
01/01/2004 - "Clinical trials of the antitumor activity of chelators have been largely limited to DFO, which has been extensively studied as a consequence of its approved use for treatment of secondary iron overload. "
08/01/1995 - "This study presents new data favoring the potential clinical interest of this new class of chelating agents in the treatment of human iron overload."
07/01/2014 - "Collated data are presented on the pathophysiological impact of iron overload; measuring techniques and chelating agents' therapy positive impact on hematological status and overall survival are discussed. "

03/10/2013 - "These changes can be therapeutically manipulated by the use of novel chelators that have recently been shown to be highly effective in terms of inhibiting tumor growth. "
08/01/2012 - "These findings suggest that strong Zn-chelating agents may be useful in the treatment of apoptosis-resistant human cancers."
10/03/2006 - "The aim of this study was to evaluate the antitumor activity and Fe chelation efficacy of a new class of Fe chelators using human tumors. "
10/01/1999 - "In conclusion, (111)In-activity in tumors consists of intracellular and extracellular components, and the extracellular (111)In may be cleared by chelators. "
01/01/2011 - "The objective of this study was to investigate the relationship between the thermodynamic stability of the (64)Cu-complexes of five commonly used bifunctional chelators (BFCs) and the biodistribution of an antibody labeled with (64)Cu using these chelators in tumor-bearing mice. "

06/01/2012 - "Further studies are needed to assess the possible use of CCBs as non-traditional chelating agents for treatment of iron overload cardiomyopathy."
10/01/2013 - "Iron chelators and nuclear magnetic resonance imaging (MRI) techniques for assessing iron loading in liver and heart have greatly improved survival of thalassemic patients suffering iron overload-associated cardiomyopathy. "
05/01/2000 - "This picture rationalizes the limited protective efficacy of antioxidants against chronic cardiomyopathy vis-à-vis the better protection offered by iron chelators, and forms the basis for developing analogues which produce less DOXol."
01/01/2007 - "Aroylhydrazone lipophilic iron chelators have shown promising results in the rabbit model of daunorubicin-induced cardiomyopathy as well as in cellular models. "
01/01/2009 - "The objective of this study was to determine the efficacy of dietary supplementation with the metal chelators, trientine or citric acid, in preventing the development of cardiomyopathy in the Zucker diabetic rat. "

10/01/2014 - "Relationship among chelator adherence, change in chelators, and quality of life in thalassemia."
05/01/1992 - "[New therapeutic trends in thalassemia: oral chelating agents]."
10/07/1964 - "CHELATING AGENTS IN THE DIAGNOSIS AND TREATMENT OF IRON OVERLOAD IN THALASSEMIA."
01/01/2008 - "Iron chelators may be effective in preventing vascular damage in patients with high concentrations of NTBI as found in thalassemia."
01/01/2010 - "Acknowledging the challenges of assessing chelators with diverse properties and imperfect comparative data, the purpose of this review is to summarize the last 4 years of studies that have improved our understanding of the applications and limitations of iron chelators in various settings for thalassemia patients, and to point out areas for much-needed future research."

01/01/2012 - "This is particularly evident in disorders such as Alzheimer's disease (AD), where the use of metal chaperones (that transport metals), as opposed to chelators (which exclude metals from biological interactions), may prove to be the first truly disease modifying approach for this condition. "
06/18/2010 - "Chelators have the potential to treat the underlying cause of Alzheimer's disease (AD), but their therapeutic use is hampered by their poor targeting and poor permeability to the brain and/or toxic effects. "
07/23/2009 - "A novel strategy to develop site-activated multifunctional chelators for targeting multiple etiologies of Alzheimer's disease is reported. "
09/14/2007 - "Alzheimer's disease), or for the testing of Zn2+ chelators including putative drug candidates. "
01/03/2005 - "Oxidative stress and excessive redox metals have been implicated in the pathogenesis of Alzheimer's disease (AD), which leads to the tentative employment of radical scavengers and metal chelators in clinical therapy of AD. "